Back

Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

21 May 2022 (08:30 - 18:50)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Chronic Heart Failure 1 Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Michael Boehm

Saarland University Hospital, Homburg (Germany)

38 More presentations in this session

Presentation thumbnail
Novel kidney injury markers (NGAL and KIM-1) and outcomes in patients with heart failure- Systematic review and meta-analysis
Doctor A. Kumar (Little Rock, US)
Abstract Slides
Presentation thumbnail
Right ventricular dilatation as a manifestation of right ventricular dysfunction in patients with HFrEF: a new concept of evaluation
Doctor J. Benes (Prague, CZ)
Abstract Slides
Presentation thumbnail
Combination treatment by epoxyeicosatrienoic acid analog and angiotensin-convertase enzyme inhibitor in congestive heart failure: a preclinical study on animal model
Doctor P. Kala (Prague, CZ)
Abstract Slides
Presentation thumbnail
Long-term prognostic implications of in-hospital changes in N-terminal pro-B-type natriuretic peptide levels among hospitalized patients with atrial fibrillation with or without heart failure
Mr A. Samaras (Thessaloniki, GR)
Abstract Slides
Presentation thumbnail
Perirenal adipose tissue is associated with renal dysfunction in patients with heart failure and preserved ejection fraction
Ms E. Boorsma (Groningen, NL)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Chronic Heart Failure 1

The Event

Event poster

Heart Failure 2022

21 May 2022 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources